Status | Study |
Recruiting |
Study Name: Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Condition: Cervical Adenosarcoma Cervical Adenosquamous Carcinoma Cer Date: 2013-12-19 Interventions: Biological: Bevacizumab Given |
Recruiting |
Study Name: Suitability of DCE-MRI for Detection of Vascular Changes After VBT Condition: Carcinoma of the Cervix, Carcinoma or Carcinosarcoma of the Uterus Date: 2013-11-11 Interventions: Radiation: Radiotherapy |
Recruiting |
Study Name: Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Condition: Endometrial Adenosquamous Carcinoma Endometrial Clear Cell Adenocarcinoma Date: 2013-09-03 Interventions: Drug: Cabozantinib S-malate Gi |
Withdrawn |
Study Name: Quadrant Versus Superficial Parotidectomy Condition: Pleomorphic Adenoma of the Parotid Gland Date: 2012-05-24 Interventions: Procedure: Quadrant parotidectomy |
Recruiting |
Study Name: A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma Condition: Recurrent Endometrial Cancer Date: 2011-09-28 Interventions: Drug: Lapatinib and ixempra Ixabepilone 40 mg/m2 Lapatinib 250 mg |
Active, not recruiting |
Study Name: Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Condition: Endometrial Adenocarcinoma Endometrial Adenosquamous Carcinoma Date: 2011-09-24 Interventions: Drug: Carboplatin Given IV |
Recruiting |
Study Name: Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer Condition: Stage IA Uterine Sarcoma Stage IB Uterine Sarcoma Stage IC Date: 2011-06-03 Interventions: Drug: paclitaxel Given IV |
Completed |
Study Name: Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Condition: Recurrent Uterine Corpus Sarcoma Uterine Carcinosarcoma Date: 2010-11-23 Interventions: Drug: Pazopanib Hydrochloride Given PO Other Names: |
Active, not recruiting |
Study Name: Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Condition: Recurrent Uterine Sarcoma Uterine Carcinosarcoma Date: 2010-07-22 Interventions: Drug: ixabepilone Given IV |
Active, not recruiting |
Study Name: Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Condition: Cognitive Side Effects of Cancer Therapy Malignant Ovarian Epithelial Tumor Date: 2010-03-03 Interventions: Procedure: Cognitive Assessment |